$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

$esta Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168875723000058 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$48.56M	$46.52M
YoY Change	17.9%	20.99%
Cost Of Revenue	$18.30M	$16.45M
YoY Change	33.23%	21.67%
Gross Profit	$30.26M	$30.08M
YoY Change	10.22%	20.62%
Gross Profit Margin	62.32%	64.65%
Selling, General & Admin	$37.03M	$31.71M
YoY Change	12.35%	17.81%
% of Gross Profit	122.36%	105.41%
Research & Development	$6.947M	$6.533M
YoY Change	41.69%	81.57%
% of Gross Profit	22.96%	21.72%
Depreciation & Amortization	$600.0K	$936.0K
YoY Change	-36.84%	3644.0%
% of Gross Profit	1.98%	3.11%
Operating Expenses	$43.97M	$38.24M
YoY Change	16.15%	25.33%
Operating Profit	-$13.71M	-$8.160M
YoY Change	31.78%	46.37%
Interest Expense	$3.620M	$3.756M
YoY Change	-151.3%	63.87%
% of Operating Profit
Other Income/Expense, Net	$1.343M	$729.0K
YoY Change	-2338.33%	-73.09%
Pretax Income	-$15.82M	-$11.11M
YoY Change	-56.71%	100.8%
Income Tax	$925.0K	$830.0K
% Of Pretax Income
Net Earnings	-$16.75M	-$11.94M
YoY Change	-54.87%	101.28%
Net Earnings / Revenue	-34.48%	-25.67%
Basic Earnings Per Share	-$0.65	-$0.48
Diluted Earnings Per Share	-$0.65	-$0.48
COMMON SHARES
Basic Shares Outstanding	25.74M shares	24.42M shares
Diluted Shares Outstanding	25.62M shares	24.68M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.18M	$42.85M
YoY Change	-1.18%	-4.05%
Cash & Equivalents	$90.18M	$42.85M
Short-Term Investments
Other Short-Term Assets	$2.334M	$4.118M
YoY Change	-64.82%	37.5%
Inventory	$56.37M	$46.14M
Prepaid Expenses
Receivables	$51.40M	$41.05M
Other Receivables	$1.481M	$1.192M
Total Short-Term Assets	$209.0M	$142.0M
YoY Change	33.62%	29.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.21M	$57.05M
YoY Change	77.11%	144.84%
Goodwill	$465.0K	$465.0K
YoY Change		0.0%
Intangibles	$4.229M	$4.367M
YoY Change		-2.3%
Long-Term Investments
YoY Change
Other Assets	$1.569M	$1.437M
YoY Change	31.41%	20.65%
Total Long-Term Assets	$76.28M	$67.32M
YoY Change	75.54%	113.44%
TOTAL ASSETS
Total Short-Term Assets	$209.0M	$142.0M
Total Long-Term Assets	$76.28M	$67.32M
Total Assets	$285.3M	$209.4M
YoY Change	42.73%	47.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.36M	$20.25M
YoY Change	52.38%	21.64%
Accrued Expenses	$17.43M	$19.64M
YoY Change	-0.94%	8.76%
Deferred Revenue	$1.480M	$1.579M
YoY Change		24.72%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$43.27M	$41.47M
YoY Change	24.52%	13.59%
LONG-TERM LIABILITIES
Long-Term Debt	$182.0M	$178.6M
YoY Change	25.08%	240.37%
Other Long-Term Liabilities	$1.992M	$1.821M
YoY Change	-47.33%	0.0%
Total Long-Term Liabilities	$184.0M	$180.5M
YoY Change	23.25%	232.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$43.27M	$41.47M
Total Long-Term Liabilities	$184.0M	$180.5M
Total Liabilities	$230.4M	$225.4M
YoY Change	25.22%	140.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$310.3M	-$293.5M
YoY Change		38.25%
Common Stock	$309.7M	$224.9M
YoY Change		1.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$54.87M	-$16.00M
YoY Change
Total Liabilities & Shareholders Equity	$285.3M	$209.4M
YoY Change	42.73%	47.9%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$16.75M	-$11.94M
YoY Change	-54.87%	101.28%
Depreciation, Depletion And Amortization	$600.0K	$936.0K
YoY Change	-36.84%	3644.0%
Cash From Operating Activities	-$28.24M	-$20.61M
YoY Change	149.25%	325.91%
INVESTING ACTIVITIES
Capital Expenditures	$9.049M	$432.0K
YoY Change	-168.09%	-45.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$9.049M	-$4.278M
YoY Change	-34.49%	-25.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	84.49M	$1.183M
YoY Change	16.83%	-30.21%
NET CHANGE
Cash From Operating Activities	-28.24M	-$20.61M
Cash From Investing Activities	-9.049M	-$4.278M
Cash From Financing Activities	84.49M	$1.183M
Net Change In Cash	47.20M	-$23.51M
YoY Change	0.06%	168.39%
FREE CASH FLOW
Cash From Operating Activities	-$28.24M	-$20.61M
Capital Expenditures	$9.049M	$432.0K
Free Cash Flow	-$37.29M	-$21.05M
YoY Change	-2003.47%	273.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Country Region CountryRegion	506
CY2023Q1	dei	City Area Code CityAreaCode	24
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	34 2400
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001688757
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38593
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Establishment Labs Holdings Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Building B15 and 25
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Coyol Free Zone
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Alajuela
CY2023Q1	dei	Entity Address Country EntityAddressCountry	CR
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common Shares, No Par Value
CY2023Q1	dei	Trading Symbol TradingSymbol	ESTA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25737847	shares
CY2023Q1	us-gaap	Cash Cash	42847000	usd
CY2022Q4	us-gaap	Cash Cash	66355000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1003000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	741000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41049000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35423000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	46141000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36583000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12004000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11543000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	142041000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	149904000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57051000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51092000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	465000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	465000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4367000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4608000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3998000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3702000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1437000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1290000	usd
CY2023Q1	us-gaap	Assets Assets	209359000	usd
CY2022Q4	us-gaap	Assets Assets	211061000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	20254000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	20034000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19638000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17237000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1579000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1688000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	41471000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	38959000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178648000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	175461000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3415000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3200000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1821000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1626000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	225355000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	219246000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24869763	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24815908	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24461693	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24407838	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	224910000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	223637000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53171000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49911000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	408070	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	408070	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2854000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	2854000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293536000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-281594000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2313000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2715000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15996000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8185000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209359000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	211061000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46524000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46524000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38452000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38452000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	16445000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	13516000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	30079000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	24936000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31706000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26913000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6533000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3598000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	38239000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	30511000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8160000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5575000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	75000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3756000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	2292000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-396000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	729000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2709000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11112000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5534000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	830000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	399000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5933000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24678113	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24678113	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24310856	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24310856	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5933000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-402000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2107000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-402000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2107000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12344000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8040000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8185000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1271000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3324000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	62000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-402000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11942000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15996000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	50739000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1702000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3434000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2107000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5933000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	47835000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11942000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5933000	usd
CY2023Q1	esta	Depreciationand Amortization Excluding Debt Discount Premium DepreciationandAmortizationExcludingDebtDiscountPremium	936000	usd
CY2022Q1	esta	Depreciationand Amortization Excluding Debt Discount Premium DepreciationandAmortizationExcludingDebtDiscountPremium	953000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	282000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	69000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-387000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	1415000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3324000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3434000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-288000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-59000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1709000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2889000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	177000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	95000	usd
CY2023Q1	esta	Property Plant And Equipment Write Down PropertyPlantAndEquipmentWriteDown	-341000	usd
CY2022Q1	esta	Property Plant And Equipment Write Down PropertyPlantAndEquipmentWriteDown	0	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-396000	usd
CY2023Q1	esta	Interest Costs Capitalized Construction In Progress InterestCostsCapitalizedConstructionInProgress	797000	usd
CY2022Q1	esta	Interest Costs Capitalized Construction In Progress InterestCostsCapitalizedConstructionInProgress	0	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3187000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	580000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5356000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5067000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8494000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	909000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	246000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-69000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	137000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	636000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1482000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2021000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2236000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1775000	usd
CY2023Q1	esta	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-175000	usd
CY2022Q1	esta	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-91000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	22000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-181000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20614000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4840000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	432000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	798000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49000	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	390000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	3797000	usd
CY2022Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	4551000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4278000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5739000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1271000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1702000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	62000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1183000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1695000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23508000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8759000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66355000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53415000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42847000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44656000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1360000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1707000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	218000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	159000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1514000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	51000	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	797000	usd
CY2022Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	0	usd
CY2023Q1	esta	Noncash Consideration Payable Relatedto Asset Acquisition NoncashConsiderationPayableRelatedtoAssetAcquisition	0	usd
CY2022Q1	esta	Noncash Consideration Payable Relatedto Asset Acquisition NoncashConsiderationPayableRelatedtoAssetAcquisition	536000	usd
CY2023Q1	esta	Number Of Manufacturing Facilities NumberOfManufacturingFacilities	2	facility
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates and management judgments reflected in the condensed </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> financial statements include items such as accounts receivable valuation and allowances, inventory valuation and allowances, valuation of acquired intangible assets, valuation of derivatives and valuation of deferred income tax assets, including tax valuation allowances. Estimates are based</span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results may differ from those estimates under different assumptions or conditions.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist principally of cash and accounts receivable. The majority of the Company’s cash is held at two financial institutions in the United States. Balances in the Company’s cash accounts exceed the Federal Deposit Insurance Corporation, or FDIC, limit of $250,000. The Company has not experienced any losses to its deposits of cash.</span></div><div style="margin-bottom:6pt"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s revenue has been derived from sales of its products in international markets, principally Europe, the Middle East, Latin America, and Asia. In the international markets in which the Company operates, the Company uses a combination of distributors and makes direct sales to customers. The Company performs ongoing credit evaluations of its distributors and customers, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s revenues were derived from the sale of Motiva Implants. During the three months ended March 31, 2023, one customer accounted for more than 10% of the Company’s revenue. During the three months ended March 31, 2022, no customer accounted for more than 10% of the Company’s revenue. One customer accounted for 13.1% and 11.5% of the Company’s trade accounts receivable balance as of March 31, 2023 and December 31, 2022, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on Avantor, Inc. (formerly NuSil Technology, LLC), or Avantor, as the sole supplier of medical-grade silicone used in Motiva Implants. During the three months ended March 31, 2023 and 2022, the Company had purchases of $13.2 million, or 55.1% of total purchases, and $7.3 million, or 31.4% of total purchases, respectively, from Avantor. As of March 31, 2023 and </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had an outstanding balance owed to this vendor of $4.9 million and $5.6 million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, unfavorable economic conditions, uncertainty of regulatory approval of the Company’s current and potential future products, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, access to capital, strategic relationships and dependence on key individuals and sole source suppliers. </span></div>Products developed by the Company require clearances from the FDA or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company is denied clearance, clearance is delayed, or the Company is unable to maintain its existing clearances, these developments could have a material adverse impact on the Company.
CY2023Q1	esta	Number Of Financial Institutions Holding Cash NumberOfFinancialInstitutionsHoldingCash	2	financial_institution
CY2023Q1	esta	Number Of Financial Institutions Holding Cash NumberOfFinancialInstitutionsHoldingCash	2	financial_institution
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2900000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2600000	usd
CY2023Q1	esta	Revenue From Contract With Customer Product Return Period RevenueFromContractWithCustomerProductReturnPeriod	P15D
CY2023Q1	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1000000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46524000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46524000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38452000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38452000	usd
CY2023Q1	esta	Revenue From Contract With Customer Product Shelf Life RevenueFromContractWithCustomerProductShelfLife	P5Y
CY2023Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P50Y
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	900000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2800000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	18781000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12549000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1949000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1666000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	25411000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	22368000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	46141000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	36583000	usd
CY2023Q1	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	5000000	usd
CY2022Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	2000000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	2134000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2598000	usd
CY2023Q1	esta	Prepaid Construction In Process PrepaidConstructionInProcess	1811000	usd
CY2022Q4	esta	Prepaid Construction In Process PrepaidConstructionInProcess	2240000	usd
CY2023Q1	esta	Prepaid Assets PrepaidAssets	1410000	usd
CY2022Q4	esta	Prepaid Assets PrepaidAssets	991000	usd
CY2023Q1	us-gaap	Prepaid Taxes PrepaidTaxes	1192000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1400000	usd
CY2023Q1	esta	Prepaid Services PrepaidServices	576000	usd
CY2022Q4	esta	Prepaid Services PrepaidServices	685000	usd
CY2023Q1	us-gaap	Supplies Supplies	359000	usd
CY2022Q4	us-gaap	Supplies Supplies	433000	usd
CY2023Q1	esta	Prepaid Clinical Trial Costs Current PrepaidClinicalTrialCostsCurrent	211000	usd
CY2022Q4	esta	Prepaid Clinical Trial Costs Current PrepaidClinicalTrialCostsCurrent	300000	usd
CY2023Q1	esta	Prepaid Warranty And Distribution Rights Current PrepaidWarrantyAndDistributionRightsCurrent	193000	usd
CY2022Q4	esta	Prepaid Warranty And Distribution Rights Current PrepaidWarrantyAndDistributionRightsCurrent	238000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4118000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2658000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12004000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11543000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	71439000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64713000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14388000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13621000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57051000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51092000	usd
CY2022Q1	esta	Depreciation And Amortization Property Plant And Equipment DepreciationAndAmortizationPropertyPlantAndEquipment	600000	usd
CY2023Q1	esta	Depreciation And Amortization Property Plant And Equipment DepreciationAndAmortizationPropertyPlantAndEquipment	600000	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6364000	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5245000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4557000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4097000	usd
CY2023Q1	esta	Accrued Stock Option Grant Bonus Current AccruedStockOptionGrantBonusCurrent	4500000	usd
CY2022Q4	esta	Accrued Stock Option Grant Bonus Current AccruedStockOptionGrantBonusCurrent	4500000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	782000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	688000	usd
CY2023Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	688000	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	712000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1572000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1203000	usd
CY2023Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	314000	usd
CY2022Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	171000	usd
CY2023Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	183000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	130000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	678000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19638000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17237000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1579000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1688000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1579000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1688000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1840000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1670000	usd
CY2023Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	19000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	44000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1821000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1626000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	465000	usd
CY2023Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Goodwill Goodwill	465000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	usd
CY2023Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	usd
CY2023Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	9941000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5574000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4367000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	291000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	9894000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5286000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4608000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	868000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1069000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	941000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	479000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	290000	usd
CY2023Q1	esta	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	429000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4076000	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	178648000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	277000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	147000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3998000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3702000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	782000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	688000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3415000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3200000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4197000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3888000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	268000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	147000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	478000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	807000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1065000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	923000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	840000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	728000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	802000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5165000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	968000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4197000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24869763	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24815908	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24461693	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24407838	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6040011	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5157807	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3324000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3434000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1873165	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.73
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y21D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	47273000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.17
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	92519	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	73.57
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52148	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.40
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	28553	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	72.31
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1884983	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.31
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	47365000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1062890	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	32.03
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	39200000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	52148	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.40
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2500000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22000000	usd
CY2023Q1	esta	Employee And Non Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Notyet Recognized Periodfor Recognition EmployeeAndNonEmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotyetRecognizedPeriodforRecognition	P2Y4M24D
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11942000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5933000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24678113	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24678113	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24310856	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24310856	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1837663	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1795144	shares
CY2022	esta	Payments For Consulting Services PaymentsForConsultingServices	87500	usd
CY2023Q1	esta	Payments For Consulting Services PaymentsForConsultingServices	43750	usd
CY2023Q1	esta	Number Of Employees Represented By A Labor Union NumberOfEmployeesRepresentedByALaborUnion	47	employee

Files In Submission

Name	View Source	Status
esta-20230331_cal.xml	Edgar Link	unprocessable
esta-20230331_def.xml	Edgar Link	unprocessable
esta-20230331_pre.xml	Edgar Link	unprocessable
0001688757-23-000058-index-headers.html	Edgar Link	pending
0001688757-23-000058-index.html	Edgar Link	pending
0001688757-23-000058.txt	Edgar Link	pending
0001688757-23-000058-xbrl.zip	Edgar Link	pending
esta-20230331.htm	Edgar Link	pending
esta-20230331.xsd	Edgar Link	pending
exhibit311q12023.htm	Edgar Link	pending
exhibit312q12023.htm	Edgar Link	pending
exhibit321q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
esta-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
esta-20230331_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

2023 Q2 Form 10-Q Financial Statement

#000168875723000058 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESTA ESTABLISHMENT LABS HOLDINGS INC. Stock $esta

2023 Q2 Form 10-Q Financial Statement

#000168875723000058 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESTA
ESTABLISHMENT LABS HOLDINGS INC. Stock $esta